Birgitta Grundmark's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
IntroductionThe safety profile of remdesivir, conditionally approved for COVID-19, was limited at its 2020 introduction. Adverse drug reactions (ADRs) for medicines are collected in VigiBase, the WHO Global Database of Individual Case Safety Reports (ICSRs).Objective
This study aimed to provide a descriptive analysis of COVID-19 ICSR data focusing...
Citations
... 16 It is also possible that this real-world Veteran cohort had greater comorbidity than those enrolled in clinical trials. Remdesivir-associated liver injury has been observed in other real-world cohorts of critically ill patients with COVID-19 17 and pharmacovigilance studies 18,19 ; it has been associated with liver failure 20 and increased mortality. 21 Our study was not designed to analyze clinical outcomes of those observed to exhibit ALT elevations in the remdesivir-treated group. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/299615606853632-1448445335252_Q64/Elena-Rocca.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/517384895434752-1500365579745_Q64/Ruth-Savage-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1165051494965249-1654781330227_Q64/Sara-Vidlin.jpg)
